ID   EPHB1_HUMAN             Reviewed;         984 AA.
AC   P54762; A8K593; B3KTB2; B5A969; O43569; O95142; O95143; Q0VG87;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-OCT-2022, entry version 221.
DE   RecName: Full=Ephrin type-B receptor 1;
DE            EC=2.7.10.1;
DE   AltName: Full=ELK;
DE   AltName: Full=EPH tyrosine kinase 2;
DE   AltName: Full=EPH-like kinase 6;
DE            Short=EK6;
DE            Short=hEK6;
DE   AltName: Full=Neuronally-expressed EPH-related tyrosine kinase;
DE            Short=NET;
DE   AltName: Full=Tyrosine-protein kinase receptor EPH-2;
DE   Flags: Precursor;
GN   Name=EPHB1; Synonyms=ELK, EPHT2, HEK6, NET;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=8666391; DOI=10.1006/geno.1995.9985;
RA   Tang X.X., Biegel J.A., Nycum L.M., Yoshioka A., Brodeur G.M.,
RA   Pleasure D.E., Ikegaki N.;
RT   "cDNA cloning, molecular characterization, and chromosomal localization of
RT   NET(EPHT2), a human EPH-related receptor protein-tyrosine kinase gene
RT   preferentially expressed in brain.";
RL   Genomics 29:426-437(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CELL ADHESION, FUNCTION
RP   IN JUN CASCADE ACTIVATION, INTERACTION WITH NCK1, MUTAGENESIS OF TYR-594
RP   AND LYS-651, AND VARIANT TRP-973.
RC   TISSUE=Kidney;
RX   PubMed=9430661; DOI=10.1074/jbc.273.3.1303;
RA   Stein E., Huynh-Do U., Lane A.A., Cerretti D.P., Daniel T.O.;
RT   "Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to
RT   c-Jun kinase.";
RL   J. Biol. Chem. 273:1303-1308(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 18-32.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [8]
RP   INTERACTION WITH GRB2 AND GRB10, MUTAGENESIS OF TYR-928, AND
RP   PHOSPHORYLATION AT TYR-928.
RX   PubMed=8798570; DOI=10.1074/jbc.271.38.23588;
RA   Stein E., Cerretti D.P., Daniel T.O.;
RT   "Ligand activation of ELK receptor tyrosine kinase promotes its association
RT   with Grb10 and Grb2 in vascular endothelial cells.";
RL   J. Biol. Chem. 271:23588-23593(1996).
RN   [9]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [10]
RP   FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, INTERACTION WITH ACP1,
RP   AND MUTAGENESIS OF TYR-928.
RX   PubMed=9499402; DOI=10.1101/gad.12.5.667;
RA   Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D.,
RA   Van Etten R.L., Daniel T.O.;
RT   "Eph receptors discriminate specific ligand oligomers to determine
RT   alternative signaling complexes, attachment, and assembly responses.";
RL   Genes Dev. 12:667-678(1998).
RN   [11]
RP   INTERACTION WITH EPHB6.
RX   PubMed=11713248; DOI=10.1074/jbc.m108011200;
RA   Freywald A., Sharfe N., Roifman C.M.;
RT   "The kinase-null EphB6 receptor undergoes transphosphorylation in a complex
RT   with EphB1.";
RL   J. Biol. Chem. 277:3823-3828(2002).
RN   [12]
RP   INTERACTION WITH GRB7, FUNCTION, PHOSPHORYLATION AT TYR-928, AND
RP   MUTAGENESIS OF TYR-928.
RX   PubMed=12223469; DOI=10.1074/jbc.m203165200;
RA   Han D.C., Shen T.L., Miao H., Wang B., Guan J.L.;
RT   "EphB1 associates with Grb7 and regulates cell migration.";
RL   J. Biol. Chem. 277:45655-45661(2002).
RN   [13]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN ERK CASCADE ACTIVATION, INTERACTION
RP   WITH GRB2; SHC1 AND SRC, AND MUTAGENESIS OF TYR-600 AND TYR-778.
RX   PubMed=12925710; DOI=10.1083/jcb.200302073;
RA   Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.;
RT   "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote
RT   chemotaxis.";
RL   J. Cell Biol. 162:661-671(2003).
RN   [14]
RP   FUNCTION IN ERK CASCADE ACTIVATION, UBIQUITINATION BY CBL, INTERACTION WITH
RP   CBL, MUTAGENESIS OF LYS-651, AUTOPHOSPHORYLATION, IDENTIFICATION OF EFNB1
RP   AS LIGAND, AND SUBCELLULAR LOCATION.
RX   PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x;
RA   Fasen K., Cerretti D.P., Huynh-Do U.;
RT   "Ligand binding induces Cbl-dependent EphB1 receptor degradation through
RT   the lysosomal pathway.";
RL   Traffic 9:251-266(2008).
RN   [15]
RP   STRUCTURE BY NMR OF 899-984.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C-terminal SAM-domain of mouse ephrin type-B
RT   receptor 1 precursor (EC 2.7.1.112).";
RL   Submitted (JUL-2007) to the PDB data bank.
RN   [16]
RP   STRUCTURE BY NMR OF 434-528.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the FN3 domain of human ephrin type-B receptor 1.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-18; MET-387; THR-707; VAL-719; GLN-743;
RP   THR-912 AND MET-981.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       transmembrane ephrin-B family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into neighboring
CC       cells. The signaling pathway downstream of the receptor is referred to
CC       as forward signaling while the signaling pathway downstream of the
CC       ephrin ligand is referred to as reverse signaling. Cognate/functional
CC       ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During
CC       nervous system development, regulates retinal axon guidance redirecting
CC       ipsilaterally ventrotemporal retinal ganglion cells axons at the optic
CC       chiasm midline. This probably requires repulsive interaction with
CC       EFNB2. In the adult nervous system together with EFNB3, regulates
CC       chemotaxis, proliferation and polarity of the hippocampus neural
CC       progenitors. In addition to its role in axon guidance also plays an
CC       important redundant role with other ephrin-B receptors in development
CC       and maturation of dendritic spines and synapse formation. May also
CC       regulate angiogenesis. More generally, may play a role in targeted cell
CC       migration and adhesion. Upon activation by EFNB1 and probably other
CC       ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades
CC       to regulate cell migration and adhesion respectively. Involved in the
CC       maintenance of the pool of satellite cells (muscle stem cells) by
CC       promoting their self-renewal and reducing their activation and
CC       differentiation (By similarity). {ECO:0000250|UniProtKB:Q8CBF3,
CC       ECO:0000269|PubMed:12223469, ECO:0000269|PubMed:12925710,
CC       ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:9430661,
CC       ECO:0000269|PubMed:9499402}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer
CC       is composed of an ephrin dimer and a receptor dimer. Oligomerization is
CC       probably required to induce biological responses (By similarity).
CC       Interacts with EPHB6; transphosphorylates EPHB6 to form an active
CC       signaling complex. Interacts with PICK1 (By similarity). Interacts
CC       (through Tyr-594) with NCK1 (via SH2 domain); activates the JUN cascade
CC       to regulate cell adhesion (By similarity). The ligand-activated form
CC       interacts (through Tyr-928) with GRB7 and GRB10 (via SH2 domains). The
CC       ligand-activated form interacts (residues within the catalytic domain)
CC       with GRB2 (via SH2 domain). Interacts with GRB2, SHC1 and SRC;
CC       activates the MAPK/ERK cascade to regulate cell migration. Interacts
CC       with CBL; regulates receptor degradation through ubiquitination.
CC       Interacts with ACP1. {ECO:0000250|UniProtKB:Q8CBF3,
CC       ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:12223469,
CC       ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9430661,
CC       ECO:0000269|PubMed:9499402}.
CC   -!- INTERACTION:
CC       P54762; Q13322: GRB10; NbExp=2; IntAct=EBI-80252, EBI-80275;
CC       P54762; P62993: GRB2; NbExp=2; IntAct=EBI-80252, EBI-401755;
CC       P54762; Q14451: GRB7; NbExp=4; IntAct=EBI-80252, EBI-970191;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18034775};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:18034775}.
CC       Early endosome membrane {ECO:0000269|PubMed:18034775}. Cell projection,
CC       dendrite {ECO:0000250|UniProtKB:Q8CBF3}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P54762-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54762-5; Sequence=VSP_056017;
CC       Name=3;
CC         IsoId=P54762-6; Sequence=VSP_056018, VSP_056019;
CC   -!- TISSUE SPECIFICITY: Preferentially expressed in brain.
CC   -!- PTM: Phosphorylated. Autophosphorylation is stimulated by the ligand
CC       EFNB1. Required for interaction with SH2 domain-containing interactors,
CC       for activation of the MAPK/ERK and JUN signaling cascades and for
CC       ubiquitination by CBL. {ECO:0000269|PubMed:12223469,
CC       ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:8798570}.
CC   -!- PTM: Ubiquitinated; (EFNB1)ligand-induced poly- and/or multi-
CC       ubiquitination by CBL is regulated by SRC and leads to lysosomal
CC       degradation. {ECO:0000269|PubMed:18034775}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB94627.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305};
CC       Sequence=AAB94628.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305};
CC       Sequence=AAD02031.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L40636; AAB08520.1; -; mRNA.
DR   EMBL; AF037331; AAD02030.1; -; mRNA.
DR   EMBL; AF037332; AAD02031.1; ALT_SEQ; mRNA.
DR   EMBL; AF037333; AAB94627.1; ALT_SEQ; mRNA.
DR   EMBL; AF037334; AAB94628.1; ALT_SEQ; mRNA.
DR   EMBL; EU826607; ACF47643.1; -; mRNA.
DR   EMBL; AK095305; BAG53024.1; -; mRNA.
DR   EMBL; AK291208; BAF83897.1; -; mRNA.
DR   EMBL; AC016931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016951; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC063918; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092969; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC111744; AAI11745.1; -; mRNA.
DR   CCDS; CCDS46921.1; -. [P54762-1]
DR   RefSeq; NP_004432.1; NM_004441.4. [P54762-1]
DR   PDB; 2DJS; NMR; -; A=434-528.
DR   PDB; 2EAO; NMR; -; A=899-984.
DR   PDB; 3ZFX; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I=602-896.
DR   PDB; 5MJA; X-ray; 2.14 A; A/B=602-896.
DR   PDB; 5MJB; X-ray; 2.23 A; A/B=602-896.
DR   PDB; 6UMW; X-ray; 1.98 A; A=602-896.
DR   PDB; 7KPL; X-ray; 2.71 A; A=611-889.
DR   PDB; 7KPM; X-ray; 1.61 A; A=611-889.
DR   PDBsum; 2DJS; -.
DR   PDBsum; 2EAO; -.
DR   PDBsum; 3ZFX; -.
DR   PDBsum; 5MJA; -.
DR   PDBsum; 5MJB; -.
DR   PDBsum; 6UMW; -.
DR   PDBsum; 7KPL; -.
DR   PDBsum; 7KPM; -.
DR   AlphaFoldDB; P54762; -.
DR   SMR; P54762; -.
DR   BioGRID; 108361; 19.
DR   IntAct; P54762; 27.
DR   MINT; P54762; -.
DR   STRING; 9606.ENSP00000381097; -.
DR   BindingDB; P54762; -.
DR   ChEMBL; CHEMBL5072; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P54762; -.
DR   GuidetoPHARMACOLOGY; 1830; -.
DR   GlyGen; P54762; 4 sites.
DR   iPTMnet; P54762; -.
DR   PhosphoSitePlus; P54762; -.
DR   BioMuta; EPHB1; -.
DR   DMDM; 1706663; -.
DR   EPD; P54762; -.
DR   jPOST; P54762; -.
DR   MassIVE; P54762; -.
DR   MaxQB; P54762; -.
DR   PaxDb; P54762; -.
DR   PeptideAtlas; P54762; -.
DR   PRIDE; P54762; -.
DR   ProteomicsDB; 3673; -.
DR   ProteomicsDB; 56716; -. [P54762-1]
DR   Antibodypedia; 33398; 584 antibodies from 39 providers.
DR   DNASU; 2047; -.
DR   Ensembl; ENST00000398015.8; ENSP00000381097.3; ENSG00000154928.19. [P54762-1]
DR   Ensembl; ENST00000493838.1; ENSP00000419574.1; ENSG00000154928.19. [P54762-5]
DR   GeneID; 2047; -.
DR   KEGG; hsa:2047; -.
DR   MANE-Select; ENST00000398015.8; ENSP00000381097.3; NM_004441.5; NP_004432.1.
DR   UCSC; uc003eqt.4; human. [P54762-1]
DR   CTD; 2047; -.
DR   DisGeNET; 2047; -.
DR   GeneCards; EPHB1; -.
DR   HGNC; HGNC:3392; EPHB1.
DR   HPA; ENSG00000154928; Tissue enhanced (brain).
DR   MIM; 600600; gene.
DR   neXtProt; NX_P54762; -.
DR   OpenTargets; ENSG00000154928; -.
DR   PharmGKB; PA27824; -.
DR   VEuPathDB; HostDB:ENSG00000154928; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000155297; -.
DR   HOGENOM; CLU_000288_141_0_1; -.
DR   InParanoid; P54762; -.
DR   OMA; MACKACP; -.
DR   PhylomeDB; P54762; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P54762; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P54762; -.
DR   SIGNOR; P54762; -.
DR   BioGRID-ORCS; 2047; 6 hits in 1105 CRISPR screens.
DR   ChiTaRS; EPHB1; human.
DR   EvolutionaryTrace; P54762; -.
DR   GeneWiki; EPH_receptor_B1; -.
DR   GenomeRNAi; 2047; -.
DR   Pharos; P54762; Tchem.
DR   PRO; PR:P54762; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P54762; protein.
DR   Bgee; ENSG00000154928; Expressed in cortical plate and 137 other tissues.
DR   ExpressionAtlas; P54762; baseline and differential.
DR   Genevisible; P54762; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0032433; C:filopodium tip; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IDA:UniProtKB.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; ISS:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:0021934; P:hindbrain tangential cell migration; IEA:Ensembl.
DR   GO; GO:0001771; P:immunological synapse formation; IEA:Ensembl.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:1902725; P:negative regulation of satellite cell differentiation; ISS:UniProtKB.
DR   GO; GO:1902723; P:negative regulation of skeletal muscle satellite cell proliferation; ISS:UniProtKB.
DR   GO; GO:0061351; P:neural precursor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0022008; P:neurogenesis; ISS:UniProtKB.
DR   GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:1901214; P:regulation of neuron death; IMP:UniProtKB.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; ISS:UniProtKB.
DR   GO; GO:0014719; P:skeletal muscle satellite cell activation; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10476; EphR_LBD_B1; 1.
DR   CDD; cd00063; FN3; 2.
DR   CDD; cd09551; SAM_EPH-B1; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034231; EphB1_rcpt_lig-bd.
DR   InterPro; IPR042819; EphB1_SAM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Cell projection; Direct protein sequencing; Endosome;
KW   Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           18..984
FT                   /note="Ephrin type-B receptor 1"
FT                   /id="PRO_0000016824"
FT   TOPO_DOM        18..540
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        541..563
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        564..984
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          19..201
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          322..432
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          433..528
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          619..882
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          911..975
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   MOTIF           982..984
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        744
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         625..633
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         651
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         600
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P54753"
FT   MOD_RES         928
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        334
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        426
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        480
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..439
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056017"
FT   VAR_SEQ         158..242
FT                   /note="VNTEVRSFGPLTRNGFYLAFQDYGACMSLLSVRVFFKKCPSIVQNFAVFPET
FT                   MTGAESTSLVIARGTCIPNAEEVDVPIKLYCNG -> LALQGHSRPARKLKAAPTAPPT
FT                   AAPLQRRLPSAPVGPVITERTLTLQKWHALASHQVPAMLSPSSMRRPSFWSGTLQGRQV
FT                   GGMM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056018"
FT   VAR_SEQ         243..984
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056019"
FT   VARIANT         18
FT                   /note="M -> V (in dbSNP:rs55650774)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042165"
FT   VARIANT         87
FT                   /note="T -> S (in dbSNP:rs1042794)"
FT                   /id="VAR_011801"
FT   VARIANT         152
FT                   /note="G -> R (in dbSNP:rs1042793)"
FT                   /id="VAR_011802"
FT   VARIANT         367
FT                   /note="R -> G (in dbSNP:rs1042789)"
FT                   /id="VAR_011803"
FT   VARIANT         387
FT                   /note="T -> M (in dbSNP:rs56396912)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042166"
FT   VARIANT         485
FT                   /note="R -> S (in dbSNP:rs1042788)"
FT                   /id="VAR_011804"
FT   VARIANT         707
FT                   /note="S -> T (in an ovarian undifferentiated carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042167"
FT   VARIANT         719
FT                   /note="I -> V (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042168"
FT   VARIANT         743
FT                   /note="R -> Q (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1338928289)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042169"
FT   VARIANT         847
FT                   /note="M -> T (in dbSNP:rs1042785)"
FT                   /id="VAR_011805"
FT   VARIANT         912
FT                   /note="A -> T (in dbSNP:rs56345346)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042170"
FT   VARIANT         973
FT                   /note="R -> W (in dbSNP:rs1042784)"
FT                   /evidence="ECO:0000269|PubMed:9430661"
FT                   /id="VAR_058479"
FT   VARIANT         981
FT                   /note="T -> M (in dbSNP:rs56186270)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042171"
FT   MUTAGEN         594
FT                   /note="Y->F: Loss of interaction with NCK1."
FT                   /evidence="ECO:0000269|PubMed:9430661"
FT   MUTAGEN         600
FT                   /note="Y->F: Loss of interaction with SHC1 and SRC."
FT                   /evidence="ECO:0000269|PubMed:12925710"
FT   MUTAGEN         651
FT                   /note="K->R: Kinase-dead mutant. Unable to
FT                   autophosphorylate, to interact with SH2 domain-containing
FT                   interactors, to activate the MAPK/ERK and JUN signaling
FT                   cascades. Not ubiquitinated by CBL."
FT                   /evidence="ECO:0000269|PubMed:18034775,
FT                   ECO:0000269|PubMed:9430661"
FT   MUTAGEN         778
FT                   /note="Y->F: Loss of interaction with SHC1."
FT                   /evidence="ECO:0000269|PubMed:12925710"
FT   MUTAGEN         928
FT                   /note="Y->F: Disrupts binding with the GRB10 SH2 domain,
FT                   providing evidence for phosphorylation. Disrupts
FT                   interaction with GRB7 and ACP1."
FT                   /evidence="ECO:0000269|PubMed:12223469,
FT                   ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9499402"
FT   CONFLICT        12
FT                   /note="A -> E (in Ref. 2; AAD02030/AAB94627/AAB94628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        185
FT                   /note="S -> I (in Ref. 2;
FT                   AAD02030/AAD02031/AAB94627/AAB94628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        274
FT                   /note="T -> R (in Ref. 2;
FT                   AAD02030/AAD02031/AAB94627/AAB94628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        336
FT                   /note="T -> S (in Ref. 2;
FT                   AAD02030/AAD02031/AAB94627/AAB94628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        752
FT                   /note="V -> L (in Ref. 6; AAI11745)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        813
FT                   /note="V -> H (in Ref. 2; AAD02030/AAB94627)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        819
FT                   /note="S -> Y (in Ref. 2; AAD02030/AAB94627)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        881
FT                   /note="M -> I (in Ref. 4; BAF83897)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        903
FT                   /note="L -> H (in Ref. 4; BAF83897)"
FT                   /evidence="ECO:0000305"
FT   STRAND          441..445
FT                   /evidence="ECO:0007829|PDB:2DJS"
FT   STRAND          447..453
FT                   /evidence="ECO:0007829|PDB:2DJS"
FT   STRAND          464..473
FT                   /evidence="ECO:0007829|PDB:2DJS"
FT   STRAND          482..495
FT                   /evidence="ECO:0007829|PDB:2DJS"
FT   STRAND          501..512
FT                   /evidence="ECO:0007829|PDB:2DJS"
FT   STRAND          514..517
FT                   /evidence="ECO:0007829|PDB:2DJS"
FT   STRAND          521..524
FT                   /evidence="ECO:0007829|PDB:2DJS"
FT   HELIX           616..618
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          619..627
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          632..638
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          646..652
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           659..673
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          683..687
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          689..692
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          694..698
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           705..710
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   TURN            711..714
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           718..737
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           747..749
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          750..752
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          758..760
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          783..786
FT                   /evidence="ECO:0007829|PDB:5MJB"
FT   HELIX           788..790
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           793..798
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           803..818
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   TURN            824..827
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           830..838
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           851..860
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           865..867
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           871..883
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   HELIX           885..887
FT                   /evidence="ECO:0007829|PDB:7KPM"
FT   STRAND          889..891
FT                   /evidence="ECO:0007829|PDB:3ZFX"
FT   HELIX           916..921
FT                   /evidence="ECO:0007829|PDB:2EAO"
FT   TURN            922..924
FT                   /evidence="ECO:0007829|PDB:2EAO"
FT   HELIX           926..928
FT                   /evidence="ECO:0007829|PDB:2EAO"
FT   HELIX           929..935
FT                   /evidence="ECO:0007829|PDB:2EAO"
FT   HELIX           940..943
FT                   /evidence="ECO:0007829|PDB:2EAO"
FT   HELIX           948..954
FT                   /evidence="ECO:0007829|PDB:2EAO"
FT   HELIX           959..975
FT                   /evidence="ECO:0007829|PDB:2EAO"
SQ   SEQUENCE   984 AA;  109885 MW;  8044160E24E93A92 CRC64;
     MALDYLLLLL LASAVAAMEE TLMDTRTATA ELGWTANPAS GWEEVSGYDE NLNTIRTYQV
     CNVFEPNQNN WLLTTFINRR GAHRIYTEMR FTVRDCSSLP NVPGSCKETF NLYYYETDSV
     IATKKSAFWS EAPYLKVDTI AADESFSQVD FGGRLMKVNT EVRSFGPLTR NGFYLAFQDY
     GACMSLLSVR VFFKKCPSIV QNFAVFPETM TGAESTSLVI ARGTCIPNAE EVDVPIKLYC
     NGDGEWMVPI GRCTCKPGYE PENSVACKAC PAGTFKASQE AEGCSHCPSN SRSPAEASPI
     CTCRTGYYRA DFDPPEVACT SVPSGPRNVI SIVNETSIIL EWHPPRETGG RDDVTYNIIC
     KKCRADRRSC SRCDDNVEFV PRQLGLTECR VSISSLWAHT PYTFDIQAIN GVSSKSPFPP
     QHVSVNITTN QAAPSTVPIM HQVSATMRSI TLSWPQPEQP NGIILDYEIR YYEKEHNEFN
     SSMARSQTNT ARIDGLRPGM VYVVQVRART VAGYGKFSGK MCFQTLTDDD YKSELREQLP
     LIAGSAAAGV VFVVSLVAIS IVCSRKRAYS KEAVYSDKLQ HYSTGRGSPG MKIYIDPFTY
     EDPNEAVREF AKEIDVSFVK IEEVIGAGEF GEVYKGRLKL PGKREIYVAI KTLKAGYSEK
     QRRDFLSEAS IMGQFDHPNI IRLEGVVTKS RPVMIITEFM ENGALDSFLR QNDGQFTVIQ
     LVGMLRGIAA GMKYLAEMNY VHRDLAARNI LVNSNLVCKV SDFGLSRYLQ DDTSDPTYTS
     SLGGKIPVRW TAPEAIAYRK FTSASDVWSY GIVMWEVMSF GERPYWDMSN QDVINAIEQD
     YRLPPPMDCP AALHQLMLDC WQKDRNSRPR FAEIVNTLDK MIRNPASLKT VATITAVPSQ
     PLLDRSIPDF TAFTTVDDWL SAIKMVQYRD SFLTAGFTSL QLVTQMTSED LLRIGITLAG
     HQKKILNSIH SMRVQISQSP TAMA
//
